The findings suggested that CAR-T therapy can be effective even in high-risk patients with MCL with characteristics such as TP53 lesions (17p13 deletions or TP53 mutations), blastoid/pleomorphic histology, CNS involvement, high Ki-67 index, and complex karyotype. This evidence concerns the gene MKI67 and mantle cell lymphoma.